Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BMS informed Five Prime that the randomized Phase 2 trial of cabiralizumab plus Opdivo with and without chemotherapy did not meet its primary endpoint; BMS has…
The drug at the center of BMS's $1.7B partnership with Five Prime missed in Phase 2 pancreatic cancer, raising questions about whether…
Adding the CSF1R inhibitor cabiralizumab to nivolumab did not improve PFS over standard chemo in advanced pancreatic cancer, dampening enthusiasm for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS entered an exclusive worldwide license and collaboration with Five Prime for the CSF1R antibody program including FPA008 (cabiralizumab). Five Prime received $350M upfront with up to $1.39B in development and regulatory milestones plus tiered double-digit royalties. The pivotal Opdivo + cabiralizumab pancreatic cancer trial (CARRY) failed in 2020.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. (CSF1R antibody program) (this deal) | 2015 | $1.7B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2015 deals · Bristol-Myers Squibb Company deals · Oncology deals